Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2024-12-12

Clinical Trial Update: Nicotinamide Supplementation in Glaucoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating nicotinamide supplementation for glaucoma and is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nicotinamide (nicotinamide)

Snippet

Sponsor: Singapore Eye Research Institute | Conditions: Glaucoma | Phase 3 | Status: ENROLLING_BY_INVITATION